학술논문
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region.
Document Type
Academic Journal
Author
Karuna, Shelly; Gallardo-Cartagena, Jorge A.; Theodore, Deborah; Hunidzarira, Portia; Montenegro-Idrogo, Juan; Jiani Hu; Jones, Megan; Kim, Vicky; De La Grecca, Robert; Trahey, Meg; Karg, Carissa; Takalani, Azwi; Polakowski, Laura; Hutter, Julia; Miner, Maurine D.; Erdmann, Nathan; Goepfert, Paul; Maboa, Rebone; Corey, Lawrence; Gill, Katherine; et al
Source
Subject
Language
English
ISSN
2047-2978
Abstract
Background Post-COVID conditions are characterised by persistent symptoms that negatively impact quality of life after SARS-CoV-2 diagnosis. While post-COVID risk factors and symptoms have been extensively described in localised regions, especially in the global north, post-COVID conditions remain poorly understood globally. The global, observational cohort study HVTN 405/HPTN 1901 characterises the convalescent course of SARS-CoV-2 infection among adults in North and South America and Africa. Methods We categorised the cohort by infection severity (asymptomatic, symptomatic, no oxygen requirement (NOR), non-invasive oxygen requirement (NIOR), invasive oxygen requirement (IOR)). We applied a regression model to assess correlations of demographics, co-morbidities, disease severity, and concomitant medications with COVID-19 symptom persistence and duration across global regions. Results We enrolled 759 participants from Botswana, Malawi, South Africa, Zambia, Zimbabwe, Peru, and the USA a median of 51 (interquartile range (IQR)=35-66) days post-diagnosis, from May 2020 to March 2021. 53.8% were female, 69.8% were 18-55 years old (median (md)=44 years old, IQR=33-58). Comorbidities included obesity (42.8%), hypertension (24%), diabetes (14%), human immunodeficiency virus (HIV) infection (11.6%) and lung disease (7.5%). 76.2% were symptomatic (NOR=47.4%; NIOR=22.9%; IOR=5.8%). Median COVID-19 duration among symptomatic participants was 20 days (IQR=11-35); 43.4% reported symptoms after COVID-19 resolution, 33.6% reported symptoms ≥30 days, 9.9% reported symptoms ≥60 days. Symptom duration correlated with disease severity (P<0.001, NIOR vs NOR; P=0.003, IOR vs NOR), lung disease (P=0.001), race (P<0.05, non-Hispanic Black vs White), and global region (P<0.001). Prolonged viral shedding correlated with persistent abdominal pain (odds ratio (OR) = 5.51, P < 0.05) and persistent diarrhoea (OR=6.64, P<0.01). Conclusions Post-COVID duration varied with infection severity, race, lung disease, and region. Better understanding post-COVID conditions, including regionally-diverse symptom profiles, may improve clinical assessment and management globally.